Safety and efficacy of donepezil hydrochloride in patients with mild to moderate Alzheimer's disease: Findings of an observational study

Alzheimer's disease (AD), a progressive brain disorder, is the most common cause of dementia among the elderly. Donepezil hydrochloride is a potent, reversible, and highly selective inhibitor of acetylcholinesterase (AChE). It is chemically distinct from other cholinesterase (ChE) inhibitors wh...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of psychiatry 2012-10, Vol.54 (4), p.337-343
Main Authors: Mehta, Suyog, Chandersekhar, K, Prasadrao, G, Dutt, Lakshman, Patkar, S, Nagpal, R D, Gupta, M, Raju, G S P, Praveen, K K, Prasad, B S V, Roy, T, Kushwaha, S, Nag, Jyotindra, Langade, D, Pawar, D
Format: Article
Language:English
Subjects:
Alzheimer's disease
Biomedical research
Caregivers
Cognition
Compliance
Complications and side effects
Dementia
Diagnosis
Drug dosages
Drug therapy
Likert scale
NMR
Nuclear magnetic resonance
Original
Physiological aspects
Studies
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Alzheimer's disease (AD), a progressive brain disorder, is the most common cause of dementia among the elderly. Donepezil hydrochloride is a potent, reversible, and highly selective inhibitor of acetylcholinesterase (AChE). It is chemically distinct from other cholinesterase (ChE) inhibitors which are effective in the treatment of AD. To evaluate the safety and efficacy of donepezil hydrochloride therapy over a 12 weeks period in patients with mild to moderate AD in Indian population. In this post-marketing study, patients with mild to moderate AD received oral donepezil hydrochloride 5 mg/day for 4 weeks followed by 10 mg/day for 8 weeks. Patients were assessed 4 times weekly for cognition on 'Mini Mental Status Examination (MMSE) scale', and function on 'Activities of Daily Living (ADL) index'. Clinicians and caregivers assessment of safety and efficacy was assessed on a 5-point rating scale. One hundred and seventy two of one hundred and eighty two patients completed 12 weeks of study period. MMSE score significantly improved (P90% patients, respectively. Adverse events were consistent with the known pharmacological and safety profile of donepezil. Donepezil is well tolerated in Indian patients with mild to moderate AD with significant improvement in cognition and function.
ISSN:0019-5545
1998-3794
DOI:10.4103/0019-5545.104820